Cargando…
Comprehensive Review of Cardiovascular Disease Risk in Nonalcoholic Fatty Liver Disease
Nonalcoholic Fatty Liver Disease (NAFLD) is a growing global phenomenon, and its damaging effects in terms of cardiovascular disease (CVD) risk are becoming more apparent. NAFLD is estimated to affect around one quarter of the world population and is often comorbid with other metabolic disorders inc...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9786069/ https://www.ncbi.nlm.nih.gov/pubmed/36547416 http://dx.doi.org/10.3390/jcdd9120419 |
_version_ | 1784858202581499904 |
---|---|
author | Josloff, Kevan Beiriger, Jacob Khan, Adnan Gawel, Richard J. Kirby, Richard S. Kendrick, Aaron D. Rao, Abhinav K. Wang, Roy X. Schafer, Michelle M. Pearce, Margaret E. Chauhan, Kashyap Shah, Yash B. Marhefka, Gregary D. Halegoua-DeMarzio, Dina |
author_facet | Josloff, Kevan Beiriger, Jacob Khan, Adnan Gawel, Richard J. Kirby, Richard S. Kendrick, Aaron D. Rao, Abhinav K. Wang, Roy X. Schafer, Michelle M. Pearce, Margaret E. Chauhan, Kashyap Shah, Yash B. Marhefka, Gregary D. Halegoua-DeMarzio, Dina |
author_sort | Josloff, Kevan |
collection | PubMed |
description | Nonalcoholic Fatty Liver Disease (NAFLD) is a growing global phenomenon, and its damaging effects in terms of cardiovascular disease (CVD) risk are becoming more apparent. NAFLD is estimated to affect around one quarter of the world population and is often comorbid with other metabolic disorders including diabetes mellitus, hypertension, coronary artery disease, and metabolic syndrome. In this review, we examine the current evidence describing the many ways that NAFLD itself increases CVD risk. We also discuss the emerging and complex biochemical relationship between NAFLD and its common comorbid conditions, and how they coalesce to increase CVD risk. With NAFLD’s rising prevalence and deleterious effects on the cardiovascular system, a complete understanding of the disease must be undertaken, as well as effective strategies to prevent and treat its common comorbid conditions. |
format | Online Article Text |
id | pubmed-9786069 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-97860692022-12-24 Comprehensive Review of Cardiovascular Disease Risk in Nonalcoholic Fatty Liver Disease Josloff, Kevan Beiriger, Jacob Khan, Adnan Gawel, Richard J. Kirby, Richard S. Kendrick, Aaron D. Rao, Abhinav K. Wang, Roy X. Schafer, Michelle M. Pearce, Margaret E. Chauhan, Kashyap Shah, Yash B. Marhefka, Gregary D. Halegoua-DeMarzio, Dina J Cardiovasc Dev Dis Review Nonalcoholic Fatty Liver Disease (NAFLD) is a growing global phenomenon, and its damaging effects in terms of cardiovascular disease (CVD) risk are becoming more apparent. NAFLD is estimated to affect around one quarter of the world population and is often comorbid with other metabolic disorders including diabetes mellitus, hypertension, coronary artery disease, and metabolic syndrome. In this review, we examine the current evidence describing the many ways that NAFLD itself increases CVD risk. We also discuss the emerging and complex biochemical relationship between NAFLD and its common comorbid conditions, and how they coalesce to increase CVD risk. With NAFLD’s rising prevalence and deleterious effects on the cardiovascular system, a complete understanding of the disease must be undertaken, as well as effective strategies to prevent and treat its common comorbid conditions. MDPI 2022-11-26 /pmc/articles/PMC9786069/ /pubmed/36547416 http://dx.doi.org/10.3390/jcdd9120419 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Josloff, Kevan Beiriger, Jacob Khan, Adnan Gawel, Richard J. Kirby, Richard S. Kendrick, Aaron D. Rao, Abhinav K. Wang, Roy X. Schafer, Michelle M. Pearce, Margaret E. Chauhan, Kashyap Shah, Yash B. Marhefka, Gregary D. Halegoua-DeMarzio, Dina Comprehensive Review of Cardiovascular Disease Risk in Nonalcoholic Fatty Liver Disease |
title | Comprehensive Review of Cardiovascular Disease Risk in Nonalcoholic Fatty Liver Disease |
title_full | Comprehensive Review of Cardiovascular Disease Risk in Nonalcoholic Fatty Liver Disease |
title_fullStr | Comprehensive Review of Cardiovascular Disease Risk in Nonalcoholic Fatty Liver Disease |
title_full_unstemmed | Comprehensive Review of Cardiovascular Disease Risk in Nonalcoholic Fatty Liver Disease |
title_short | Comprehensive Review of Cardiovascular Disease Risk in Nonalcoholic Fatty Liver Disease |
title_sort | comprehensive review of cardiovascular disease risk in nonalcoholic fatty liver disease |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9786069/ https://www.ncbi.nlm.nih.gov/pubmed/36547416 http://dx.doi.org/10.3390/jcdd9120419 |
work_keys_str_mv | AT josloffkevan comprehensivereviewofcardiovasculardiseaseriskinnonalcoholicfattyliverdisease AT beirigerjacob comprehensivereviewofcardiovasculardiseaseriskinnonalcoholicfattyliverdisease AT khanadnan comprehensivereviewofcardiovasculardiseaseriskinnonalcoholicfattyliverdisease AT gawelrichardj comprehensivereviewofcardiovasculardiseaseriskinnonalcoholicfattyliverdisease AT kirbyrichards comprehensivereviewofcardiovasculardiseaseriskinnonalcoholicfattyliverdisease AT kendrickaarond comprehensivereviewofcardiovasculardiseaseriskinnonalcoholicfattyliverdisease AT raoabhinavk comprehensivereviewofcardiovasculardiseaseriskinnonalcoholicfattyliverdisease AT wangroyx comprehensivereviewofcardiovasculardiseaseriskinnonalcoholicfattyliverdisease AT schafermichellem comprehensivereviewofcardiovasculardiseaseriskinnonalcoholicfattyliverdisease AT pearcemargarete comprehensivereviewofcardiovasculardiseaseriskinnonalcoholicfattyliverdisease AT chauhankashyap comprehensivereviewofcardiovasculardiseaseriskinnonalcoholicfattyliverdisease AT shahyashb comprehensivereviewofcardiovasculardiseaseriskinnonalcoholicfattyliverdisease AT marhefkagregaryd comprehensivereviewofcardiovasculardiseaseriskinnonalcoholicfattyliverdisease AT halegouademarziodina comprehensivereviewofcardiovasculardiseaseriskinnonalcoholicfattyliverdisease |